BMI

Badger Meter, Inc.

62
Fundamentals51/ 100
Valuation68/ 100
Upside potential52/ 100
Risk potential19/ 100

BMI has slightly lower modeled downside risk, despite its lower overall score.

PLTR

Palantir Technologies Inc.

90
Fundamentals95/ 100
Valuation88/ 100
Upside potential84/ 100
Risk potential21/ 100

PLTR has the edge over BMI overall, supported by stronger fundamentals and stronger modeled upside.

BMI Fundamentals

MetricStatus
Stable
Healthy
Healthy
Strong

BMI's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.

PLTR Fundamentals

MetricStatus
Strong
Strong
Strong
Strong

PLTR's revenue, profitability, cash flow and balance sheet are all currently strong.

BMI PE Valuation

CHEAPFAIREXPENSIVE17x33x50x66x
CHEAPFAIREXPENSIVE17x33x50x66x
LevelPEPriceVs current
Forward32x$154—
Current35x$154—
Cheap37x$160+4.3%
Fair49x$212+38%
Expensive55x$238+55%

Historical ranges are pointers, not guarantees.

BMI's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 32x next year's earnings.

PLTR PE Valuation

CHEAPFAIREXPENSIVE174x349x523x698x
CHEAPFAIREXPENSIVE174x349x523x698x
LevelPEPriceVs current
Forward75x$172—
Current120x$172—
Cheap165x$236+37%
Fair251x$359+109%
Expensive452x$646+277%

Historical ranges are pointers, not guarantees.

PLTR has the edge over BMI in the historical PE scenario, which offers more potential upside but is not a forecast.

BMI Forward outlook

MetricOutlook
Improving
Growth
Stable
Stable
Limited
Moderate

Analysts expect BMI's earnings to grow, with its revenue and profitability holding steady.

PLTR Forward outlook

MetricOutlook
Strongly improving
Strong growth
Strong growth
Strongly improving
Moderate
Moderate

PLTR has the edge over BMI on the outlook, with more favorable revenue and profitability expectations.

BMI Risk to reward

ScenarioChangePrice
Upside+21%$185.48
Downside-19%$124.20

Calculated from the latest close: $153.59 on Nov 12.

BMI trails PLTR on modeled risk to reward, with less potential upside relative to its potential downside.

PLTR Risk to reward

ScenarioChangePrice
Upside+112%$364.26
Downside-21%$136.16

Calculated from the latest close: $171.58 on Nov 12.

PLTR has a better modeled risk to reward balance than BMI, with more potential upside relative to its potential downside.

BMI Earnings Per Share

Q4 2023: $3.14Q1 2024: $3.47Q2 2024: $3.83Q3 2024: $4.03Q4 2024: $4.23Q1 2025: $4.54Q2 2025: $4.59Q3 2025: $4.70Q4 2025: $4.80Q1 2026: $4.43Q2 2026: $4.28Q3 2026: $4.33Forward: $4.87
Q4 2023: $3.14Q1 2024: $3.47Q2 2024: $3.83Q3 2024: $4.03Q4 2024: $4.23Q1 2025: $4.54Q2 2025: $4.59Q3 2025: $4.70Q4 2025: $4.80Q1 2026: $4.43Q2 2026: $4.28Q3 2026: $4.33Forward: $4.87
QuarterTTM EPSYoY
Forward$4.87+12%
Q3 2026$4.33-7.9%
Q2 2026$4.28-6.8%
Q1 2026$4.43-2.4%
Q4 2025$4.80+13%
Q3 2025$4.70+17%
Q2 2025$4.59+20%
Q1 2025$4.54+31%
Q4 2024$4.23+35%

BMI earned $4.33 per share over the past year, down 7.9% from the year before.

PLTR Earnings Per Share

Q4 2023: $0.09Q1 2024: $0.12Q2 2024: $0.17Q3 2024: $0.20Q4 2024: $0.19Q1 2025: $0.23Q2 2025: $0.30Q3 2025: $0.42Q4 2025: $0.63Q1 2026: $0.89Q2 2026: $1.17Q3 2026: $1.43Forward: $2.30
Q4 2023: $0.09Q1 2024: $0.12Q2 2024: $0.17Q3 2024: $0.20Q4 2024: $0.19Q1 2025: $0.23Q2 2025: $0.30Q3 2025: $0.42Q4 2025: $0.63Q1 2026: $0.89Q2 2026: $1.17Q3 2026: $1.43Forward: $2.30
QuarterTTM EPSYoY
Forward$2.30+61%
Q3 2026$1.43+240%
Q2 2026$1.17+290%
Q1 2026$0.89+287%
Q4 2025$0.63+232%
Q3 2025$0.42+110%
Q2 2025$0.30+76%
Q1 2025$0.23+92%
Q4 2024$0.19+111%

PLTR has the edge over BMI on earnings, with more consistent year-over-year improvement.

BMI Quarterly Revenue

Q4 2023: $182MQ1 2024: $196MQ2 2024: $217MQ3 2024: $208MQ4 2024: $205MQ1 2025: $222MQ2 2025: $238MQ3 2025: $236MQ4 2025: $221MQ1 2026: $202MQ2 2026: $222MQ3 2026: $236M
Q4 2023: $182MQ1 2024: $196MQ2 2024: $217MQ3 2024: $208MQ4 2024: $205MQ1 2025: $222MQ2 2025: $238MQ3 2025: $236MQ4 2025: $221MQ1 2026: $202MQ2 2026: $222MQ3 2026: $236M
QuarterRevenueYoY
Q3 2026$235.9M+0.1%
Q2 2026$222.3M-6.6%
Q1 2026$202.3M-9%
Q4 2025$220.7M+7.6%
Q3 2025$235.7M+13%
Q2 2025$238.1M+9.9%
Q1 2025$222.2M+13%
Q4 2024$205.2M+12%

BMI's revenue grew through 2024 and has held roughly level since: $236M last quarter, about level with the same quarter a year ago.

PLTR Quarterly Revenue

Q4 2023: $608MQ1 2024: $634MQ2 2024: $678MQ3 2024: $726MQ4 2024: $828MQ1 2025: $884MQ2 2025: $1BQ3 2025: $1.2BQ4 2025: $1.4BQ1 2026: $1.6BQ2 2026: $1.9BQ3 2026: $2.3B
Q4 2023: $608MQ1 2024: $634MQ2 2024: $678MQ3 2024: $726MQ4 2024: $828MQ1 2025: $884MQ2 2025: $1BQ3 2025: $1.2BQ4 2025: $1.4BQ1 2026: $1.6BQ2 2026: $1.9BQ3 2026: $2.3B
QuarterRevenueYoY
Q3 2026$2.3B+96%
Q2 2026$1.9B+93%
Q1 2026$1.6B+85%
Q4 2025$1.4B+70%
Q3 2025$1.2B+63%
Q2 2025$1B+48%
Q1 2025$883.9M+39%
Q4 2024$827.5M+36%

PLTR has the edge over BMI on sales, with more consistent year-over-year improvement.

BMI Free Cash Flow

Q4 2023: $36MQ1 2024: $19MQ2 2024: $34MQ3 2024: $42MQ4 2024: $47MQ1 2025: $30MQ2 2025: $41MQ3 2025: $48MQ4 2025: $51MQ1 2026: $29MQ2 2026: $22MQ3 2026: $40M
Q4 2023: $36MQ1 2024: $19MQ2 2024: $34MQ3 2024: $42MQ4 2024: $47MQ1 2025: $30MQ2 2025: $41MQ3 2025: $48MQ4 2025: $51MQ1 2026: $29MQ2 2026: $22MQ3 2026: $40M
QuarterFree cash flowYoY
Q3 2026$40.3M-16%
Q2 2026$21.9M-46%
Q1 2026$29.5M-2%
Q4 2025$50.8M+7.1%
Q3 2025$48.2M+15%
Q2 2025$40.6M+19%
Q1 2025$30.1M+60%
Q4 2024$47.4M+32%

BMI's free cash flow has been positive every quarter for seven years: $142M over the past year, down 14% from the year before.

PLTR Free Cash Flow

Q4 2023: $296MQ1 2024: $127MQ2 2024: $141MQ3 2024: $416MQ4 2024: $457MQ1 2025: $304MQ2 2025: $532MQ3 2025: $501MQ4 2025: $764MQ1 2026: $892MQ2 2026: $1.2BQ3 2026: $1.2B
Q4 2023: $296MQ1 2024: $127MQ2 2024: $141MQ3 2024: $416MQ4 2024: $457MQ1 2025: $304MQ2 2025: $532MQ3 2025: $501MQ4 2025: $764MQ1 2026: $892MQ2 2026: $1.2BQ3 2026: $1.2B
QuarterFree cash flowYoY
Q3 2026$1.2B+139%
Q2 2026$1.2B+126%
Q1 2026$891.8M+193%
Q4 2025$764M+67%
Q3 2025$500.9M+20%
Q2 2025$531.6M+276%
Q1 2025$304.1M+140%
Q4 2024$457.2M+54%

PLTR has the edge over BMI on cash flow, with more consistent year-over-year improvement.

BMI Total Shares

Q1 2024: 29MQ2 2024: 30MQ3 2024: 30MQ1 2025: 30MQ2 2025: 30MQ3 2025: 30MQ4 2025: 30MQ1 2026: 29MQ2 2026: 29MQ3 2026: 29M
Q1 2024: 29MQ2 2024: 30MQ3 2024: 30MQ1 2025: 30MQ2 2025: 30MQ3 2025: 30MQ4 2025: 30MQ1 2026: 29MQ2 2026: 29MQ3 2026: 29M
PeriodChange %Net change
Quarterly-0.9%-271K shares
1 year-2.4%-712K shares
3 years-1.9%-550K shares
5 years-1.3%-395K shares

BMI has the edge over PLTR on shareholder dilution, with a more favorable share count trend.

PLTR Total Shares

Q4 2023: 2.3BQ1 2024: 2.4BQ2 2024: 2.4BQ3 2024: 2.5BQ4 2024: 2.5BQ1 2025: 2.6BQ2 2025: 2.6BQ3 2025: 2.6BQ4 2025: 2.6BQ1 2026: 2.6BQ2 2026: 2.6BQ3 2026: 2.6B
Q4 2023: 2.3BQ1 2024: 2.4BQ2 2024: 2.4BQ3 2024: 2.5BQ4 2024: 2.5BQ1 2025: 2.6BQ2 2025: 2.6BQ3 2025: 2.6BQ4 2025: 2.6BQ1 2026: 2.6BQ2 2026: 2.6BQ3 2026: 2.6B
PeriodChange %Net change
Quarterly+0.2%+5.2M shares
1 year+0.1%+2.9M shares
3 years+11%+248M shares
5 years+31%+610M shares
Available history+184%+1.7B shares

PLTR has 2.6B diluted shares, about the same as a year ago.

BMI Net Leverage

Q4 2023: -1.5xQ1 2024: -1.4xQ2 2024: -1.5xQ3 2024: -1.6xQ4 2024: -1.8xQ1 2025: -0.7xQ2 2025: -0.9xQ3 2025: -1.1xQ4 2025: -1.2xQ1 2026: -1.1xQ2 2026: -0.6xQ3 2026: -0.4x
Q4 2023: -1.5xQ1 2024: -1.4xQ2 2024: -1.5xQ3 2024: -1.6xQ4 2024: -1.8xQ1 2025: -0.7xQ2 2025: -0.9xQ3 2025: -1.1xQ4 2025: -1.2xQ1 2026: -1.1xQ2 2026: -0.6xQ3 2026: -0.4x
QuarterNet LeverageStatus
Q3 2026-0.4xNet Cash
Q2 2026-0.6xNet Cash
Q1 2026-1.1xNet Cash
Q4 2025-1.2xNet Cash
Q3 2025-1.1xNet Cash
Q2 2025-0.9xNet Cash
Q1 2025-0.7xNet Cash
Q4 2024-1.8xNet Cash

BMI has more cash than debt.

PLTR Net Leverage

Q4 2023: -5.4xQ1 2024: -2.3xQ2 2024: -1.6xQ3 2024: -1.9xQ4 2024: -6.1xQ1 2025: -2.3xQ2 2025: -1.6xQ3 2025: -1.9xQ4 2025: -1.0xQ1 2026: -1.1xQ2 2026: -0.8xQ3 2026: -1.1x
Q4 2023: -5.4xQ1 2024: -2.3xQ2 2024: -1.6xQ3 2024: -1.9xQ4 2024: -6.1xQ1 2025: -2.3xQ2 2025: -1.6xQ3 2025: -1.9xQ4 2025: -1.0xQ1 2026: -1.1xQ2 2026: -0.8xQ3 2026: -1.1x
QuarterNet LeverageStatus
Q3 2026-1.1xNet Cash
Q2 2026-0.8xNet Cash
Q1 2026-1.1xNet Cash
Q4 2025-1.0xNet Cash
Q3 2025-1.9xNet Cash
Q2 2025-1.6xNet Cash
Q1 2025-2.3xNet Cash
Q4 2024-6.1xNet Cash

PLTR has the edge over BMI on leverage, with a lower net debt burden relative to earnings.

BMI Weekly Momentum

MetricValueStatus
RSI57.6Neutral
Stochastic74.5Neutral

BMI's weekly RSI is 58 (neutral) and its Stochastic is 75 (neutral).

PLTR Weekly Momentum

MetricValueStatus
RSI51.4Neutral
Stochastic47.4Neutral

PLTR's weekly RSI is 51 (neutral) and its Stochastic is 47 (neutral).

BMI PE vs Technology Sector

MetricBMISector medianRelative
PE35x28x27% above
PE %143521 pts below

BMI has the edge over PLTR on valuation relative to its sector.

PLTR PE vs Technology Sector

MetricPLTRSector medianRelative
PE120x28x331% above
PE %13837 pts below

PLTR is trading at 120x earnings, a 331% premium to the Technology sector's median of 28x.

BMI Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$140.89.1% above
20 week MA$137.712% above
50 week MA$144.36.4% above
100 week MA$174.912% below
200 week MA$169.69.5% below

BMI has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 9.5% below its 200-week average.

PLTR Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$185.87.6% below
20 week MA$167.62.4% above
50 week MA$157.19.2% above
100 week MA$143.819% above
200 week MA$83.3106% above

PLTR has the edge over BMI on trend strength, trading above more of its moving averages.

BMI Yearly ROI

YearStart priceEnd priceROI
2020$66.1$93.7+42%
2021$93.7$105.2+12%
2022$105.2$109.6+4.2%
2023$109.6$154.4+41%
2024$154.4$215.5+40%
2025$215.5$180.8-16%
2026 YTD$180.8$153.6-15%

BMI has finished higher in five of the last six years. It's down 15% so far in 2026.

PLTR Yearly ROI

YearStart priceEnd priceROI
2020$9.20$27.8+202%
2021$27.8$18.9-32%
2022$18.9$6.29-67%
2023$6.29$17.2+173%
2024$17.2$79.1+361%
2025$79.1$188.7+139%
2026 YTD$188.7$171.6-9.1%

PLTR has the edge over BMI on returns for 2026, with the stronger performance.

Give your agent the market.

Get API key